FDA Expands Imbruvica Use for Non-Hodgkin Lymphoma
Imbruvica (ibrutinib) can now be prescribed for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lymphoma | Macroglobulinemia | Non-Hodgkin's Lymphoma | Pharmaceuticals | Waldenstrom's Macroglobulinemia